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ABSTRACT The modern chemotherapy era started with Fleming’s discovery of ben-
zylpenicillin. He demonstrated that benzylpenicillin did not kill Mycobacterium tuber-
culosis. In this study, we found that 64 mg/liter of static benzylpenicillin concentra-
tions killed 1.16 to 1.43 log10 CFU/ml below starting inoculum of extracellular and
intracellular M. tuberculosis over 7 days. When we added the -lactamase inhibitor
avibactam, benzylpenicillin maximal kill (Emax) of extracellular log-phase-growth M.
tuberculosis was 6.80  0.45 log10 CFU/ml at a 50% effective concentration (EC50) of
15.11  2.31 mg/liter, while for intracellular M. tuberculosis it was 2.42  0.14 log10
CFU/ml at an EC50 of 6.70  0.56 mg/liter. The median penicillin (plus avibactam)
MIC against South African clinical M. tuberculosis strains (80% either multidrug or ex-
tensively drug resistant) was 2 mg/liter. We mimicked human-like benzylpenicillin
and avibactam concentration-time proﬁles in the hollow-ﬁber model of tuberculosis
(HFS-TB). The percent time above the MIC was linked to effect, with an optimal ex-
posure of 65%. At optimal exposure in the HFS-TB, the bactericidal activity in log-
phase-growth M. tuberculosis was 1.44 log10 CFU/ml/day, while 3.28 log10 CFU/ml of
intracellular M. tuberculosis was killed over 3 weeks. In an 8-week HFS-TB study of
nonreplicating persistent M. tuberculosis, penicillin-avibactam alone and the drug
combination of isoniazid, rifampin, and pyrazinamide both killed 7.0 log10 CFU/ml.
Monte Carlo simulations of 10,000 preterm infants with disseminated disease identi-
ﬁed an optimal dose of 10,000 U/kg (of body weight)/h, while for pregnant women
or nonpregnant adults with pulmonary tuberculosis the optimal dose was 25,000
U/kg/h, by continuous intravenous infusion. Penicillin-avibactam should be examined
for effect in pregnant women and infants with drug-resistant tuberculosis, to replace
injectable ototoxic and teratogenic second-line drugs.
KEYWORDS avibactam, benzylpenicillin, childhood tuberculosis, pharmacodynamics,
pregnancy, tuberculosis
The discovery of benzylpenicillin by Alexander Fleming in 1928 was an importantprimer of the modern medical era (1). Given that tuberculosis (TB) was the major
problem of the time, the drug was tried on cultures of Mycobacterium tuberculosis by
Fleming and others, but it was found to be ineffective by most (2–4). Penicillin kills
bacteria by inhibiting D-alanyl–D-alanine-cleaving peptidase (D,D-transpeptidase), which
catalyzes formation of the D,D 4¡3 cross-linkage in peptidoglycan during cell wall
synthesis. However, the predominant L,D 3¡3 cross-linkage in M. tuberculosis, catalyzed
by L,D-transpeptidases LdtMt1 and LdtMt2, is resistant to penicillin (5–7). A second reason
for poor penicillin effect could be M. tuberculosis’s class A -lactamase, BlaC (8, 9).
Semisynthetic penicillins, such as amoxicillin, as well as other -lactam classes, such as
carbapenems and cephalosporins, have been examined in combination with the
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-lactamase inhibitor clavulanate, which confers an effect against M. tuberculosis
(10–14). However, the inhibition of M. tuberculosis BlaC by clavulanate is slow and
inefﬁcient. We recently demonstrated that the non--lactam BlaC inhibitor avibactam
endowed ceftazidime, which otherwise had no antimycobacterial effect, with dramatic
efﬁcacy against M. tuberculosis and Mycobacterium avium complex (15–17). Moreover,
the targets inhibited by cephalosporins, carbapenems, and semisysnthetic penicillins in
M. tuberculosis should not be assumed to be the same as for benzylpenicillins. Finally,
the original benzylpenicillins themselves have not been examined in combination with
-lactamase inhibitors. In this study, we conﬁned the deﬁnition of penicillins to either
a benzylpenicillin (procaine or benzathine) or phenoxymethylpenicillin (penicillin V),
sensu strictu. We hypothesized that avibactam could also confer susceptibility of M.
tuberculosis to penicillin, if a lack of efﬁcacy was due solely to -lactamases and not lack
of a penicillin-binding target.
M. tuberculosis organisms in TB lung cavities exist as a mix of different metabolic
proﬁles: logarithmic-growth-phase bacteria, intracellular bacilli, semidormant bacilli
under acidic conditions (SDB), and nonreplicating persisters (NRP) (18). NRP overexpress
LdtMt2; thus, if the LdtMt2 hypothesis for the lack of penicillin effect is true, then NRP and
SDB will be even more resistant to penicillin (6, 19). Indeed, because of these subpopu-
lations of log-phase bacteria, SDB, and NRP, and because current ﬁrst line anti-TB drugs
are differentially effective against each one of these subpopulations, TB therapy relies
on drug combinations. Microbial kill of log-phase M. tuberculosis deﬁnes bactericidal
effect, and the average rate of kill in ﬁrst 2 days is termed early bactericidal activity
(EBA); the highest EBA is from isoniazid, at 0.6 log10 CFU per ml per day (20, 21).
Microbial kill of either SDB by pyrazinamide or NRP by rifampin is considered a
sterilizing effect and occurs at 0.15 log10 CFU/ml/day for rifampin and 0.10 log10
CFU/ml/day for pyrazinamide (18, 20, 22, 23). We have found that the same bactericidal
and sterilizing effect kill rates and patterns are reﬂected in our hollow-ﬁber model of TB
(HFS-TB) (20, 21, 23–26). Efﬁcacy and optimal drug exposures of antibiotics derived in
the HFS-TB have a forecasting accuracy of up to 94% in humans for bactericidal effect,
EBA, and sterilizing effect, suggesting that if a drug is efﬁcacious in the model, it likely
has good clinical effectiveness (25, 27). Indeed, the HFS-TB is a European Medicines
Agency (EMA)-approved and FDA-endorsed drug evaluation and selection methodol-
ogy (28–30). In this study, we examined the bactericidal and sterilizing effect potential
of penicillin plus avibactam in an in vitro culture system and the HFS-TB and found the
combination to be highly effective against all four different M. tuberculosis subpopu-
lations.
RESULTS
Benzylpenicillin plus avibactam is highly bactericidal in 12-well plates. On the
suggestion from K. Dheda to minimize bias and improve conﬁdence of ﬁndings, all
investigators and laboratory personnel (except D. Deshpande and T. Gumbo) were
blinded to the identity of penicillin in all our experiments. Penicillin was designated
drug X until the ﬁnal result was reported. We coincubated log-phase-growth M.
tuberculosis H37Ra with 7 different concentrations of penicillin alone in Middlebrook
7H9 broth with 10% oleic acid, albumin, dextrose, and catalase (OADC), with results
shown in Fig. 1A. Penicillin did not kill M. tuberculosis until around 64 mg/liter, when it
killed the bacteria 1.16 log10 CFU/ml below the level present on day 0. An absence of
effect at low concentrations but some effect at higher concentrations suggests that
penicillin’s effect is inhibited by a saturable process that can be overcome at high
concentrations. Next, we repeated the same experiment but this time examined all
penicillin concentrations in the presence of 15 mg/liter of avibactam, leading to results
shown in Fig. 1B. Penicillin maximal kill was 6.80  0.45 log10 CFU/ml, with a 50%
effective concentration (EC50) of 15.11  2.31 mg/liter (r2  0.988). This maximal kill
equals that of rifampin but exceeds that of either isoniazid or pyrazinamide in the same
assay (17). The EC50 is easily achieved with standard benzylpenicillin dosing: injection
or short infusion of 5 million international units (MIU) achieves a peak penicillin
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concentration of 400 mg/liter in serum (600 mg 1 MIU). Next, we performed the same
experiment but this time with adherent THP-1 monocytes infected with M. tuberculosis
H37Ra in 12-well plates. Maximal microbial kill by the penicillin alone was 1.43  0.29
log10 CFU/ml (Fig. 1C), with an EC50 of 22.26  6.22 mg/liter. With addition of
avibactam, the maximal kill increased to 2.42  0.14 log10 CFU/ml and the EC50
decreased to 6.70 0.56 mg/liter, which means that avibactam improved both efﬁcacy
(maximal kill) and potency (EC50). Thus, -lactamase inhibition alone leads to dramatic
microbial kill by penicillin.
Benzylpenicillin is efﬁcacious against intracellularM. tuberculosis in the HFS-TB
and generates little resistance. Next, we performed dose-response studies against M.
tuberculosis H37Ra-infected THP-1 human-derived monocytes in the HFS-TB. In the
presence of avibactam, the penicillin MIC for M. tuberculosis H37Ra was 8 mg/liter. We
wanted to establish the effect of benzylpenicillin-avibactam against intracellular M.
tuberculosis, as well as to identify the best dosing schedule and optimal penicillin
exposure at the same time. Thus, we examined three penicillin dosing schedules:
once-a-day doses infused over 1 h, twice-a-day doses infused over 1 h every 12 h, and
two continuous infusion doses over 24 h. We measured the concentration-time proﬁles
in each HFS-TB, with results shown in Fig. 2A. The penicillin concentrations shown in
Fig. 2A are well within those achieved in patients treated either with a 5-MIU injection
or a 24-MIU continuous infusion over 24 h. Pharmacokinetic modeling of the measured
concentrations revealed an elimination rate constant (mean  standard deviation) of
FIG 1 Effect of penicillin with and without avibactam at static concentrations. Error bars indicate SDs for three replicates. Cultures and
drugs were coincubated for 7 days at 37°C under 5% CO2 and nonshaking conditions. The relationship between penicillin
concentration (C) and Mycobacterium tuberculosis (Mtb) burden as log10 CFU/milliliter was analyzed for microbial effect (E) in log10
CFU/milliliter using the inhibitory sigmoid Emax equation, which takes the form E  Econ  Emax  CH/(CH  C50H), where Econ is M.
tuberculosis burden in nontreated controls, Emax is maximal kill, EC50 is potency or concentration mediating 50% of Emax, and H is the
Hill slope. (A) When penicillin alone was coincubated with extracellular M. tuberculosis, there was no kill at low concentrations, until
around 64 mg/liter. There was poor convergence of the curve (r2  0.61), with an EC50 of 16,027 mg/liter. (B) Addition of avibactam
dramatically increased maximum kill and improved potency2,300-fold, to 6.8 mg/liter. (C) Penicillin killed intracellularM. tuberculosis
at concentrations of 32 mg/liter, with an EC50 of 22.2 mg/liter. (D) Addition of avibactam improved the potency to 6.96 mg/liter and
the maximal kill greater than 10-fold.
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FIG 2 Penicillin dose scheduling study for intracellular M. tuberculosis. (A) Extracellular concentration-time proﬁles (symbols) shown
against intended curves, demonstrating that intended pharmacokinetics were achieved. Doses were administered as a 1-h infusion.
Regimen 1 achieved an extracellular TMIC of 28% from a human-equivalent dose of 0.41 MIU administered once a day, regimen 2 a TMIC
of 43% from a human-equivalent dose of 0.9 MIU administered once a day, and regimen 3 a TMIC of 88% from a human-equivalent dose
of 0.8 MIU administered every 12 h; regimens 4 to 6 achieved a TMIC of 100% from human-equivalent doses of 2.4 MIU administered
every 12 h (regimen 4), 5.3 MIU administered every 12 h (regimen 5), and 10.2 MIU administered every 12 h (regimen 6). (B) The
observed versus model predicted slope was 1.06 0.03 (r2 0.972), indicating minimal bias. (C) Measured intracellular concentrations
within infected monocytes were much lower than extracellular concentrations. Regimens 1 to 3 have an intracellular TMIC of 0%,
regimen 4 has a TMIC of 30%, regimen 5 has a TMIC of 58%, and regimen 6 has a TMIC of 90%. (D) Time-kill curves demonstrate that all
penicillin doses (except nontreated) killed below the day 0 burden (stasis), with no rebound growth. (E) A similar pattern was observed
using TTP. (F) The relationship between bacterial burden and extracellular TMIC is shown for each sampling day as M. tuberculosis in
nontreated HFS-TB replicates continued to grow. Maximal kill (Emax) is the span between nontreated controls and the maximal-effect
portion of each curve. (G) The size of the drug-resistant subpopulation was highest in nontreated controls, which decreased with
increasing TMIC. (H) However, when measured as a percentage of the total population, the drug-resistant subpopulation percentage
versus exposure was best described as an inverted “U” curve with ampliﬁcation of the penicillin-resistant subpopulation at a TMIC of
30 to 40%.
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0.227  0.007 per hour (Fig. 2B). We also measured the concentrations of penicillin
inside the M. tuberculosis-infected monocytes, which revealed the intracellular
concentration-time proﬁles shown in Fig. 2C. The intracellular penicillin elimination rate
constant of 0.213  0.008 per hour differed slightly from the extracellular elimination
rate, which means that the lower intracellular concentrations were likely driven by poor
penetration into the human cells and not increased intracellular elimination. Avibactam
extracellular concentrations were constant throughout at 13.54  0.26 mg/liter, per
design (slope  0; P  0.297).
Figure 2D and E show that all penicillin regimens killed the intracellular M. tuber-
culosis to a level below the day 0 bacterial burden. Maximal kill was 3.28 log10 CFU/ml
in 20 days (Fig. 2D). We also simultaneously examined bacterial burden based on time
to positivity (TTP) using the mycobacterial growth indicator tube assay (MGIT), a more
sensitive assay than CFU. Figure 2E shows that the largest increase in TTP was 2.54-fold
higher than on day 0, in the same range as with the three-drug combination ﬁrst-line
therapy in the past (31). Table 1 shows that microbial kill was highest when the
proportion of time that concentration persisted above the MIC (TMIC) was highest, and
that this was unrelated to peak concentration. Figure 2F shows that the TMIC associated
with maximal kill was65% of 24 h (r2 0.967). This means that when penicillin doses
are administered, the aim should be to exceed 65% of the day with concentrations
above the MIC for maximal effect in TB.
We also captured the M. tuberculosis subpopulation resistant to 3 times the MIC in
each HFS-TB unit, with results shown in Fig. 2G. Figure 2H shows the penicillin-resistant
subpopulation as percentage of the total bacterial burden versus TMIC, which was a
typical inverted “U” shaped curve shape that we have identiﬁed for ﬁrst-line and
second-line anti-TB drugs in the past (23, 24, 32, 33). Thus, the penicillin exposure-
versus-resistance relationship is the same shape as for standard anti-TB drugs. A TMIC of
100% completely suppressed the penicillin-resistant subpopulation (r2  0.975). How-
ever, since the penicillin-resistant subpopulation was below 1%, considered clinically
signiﬁcant, penicillin monotherapy was much less prone to resistance emergence than
each of the four ﬁrst-line drugs.
Penicillin has a dramatic bactericidal effect in the hollow-ﬁber model. Next, we
examined the efﬁcacy of penicillin in the HFS-TB with log-phase-growth M. tuberculosis
H37Ra using continuous infusion of penicillin equivalent to 1 MIU/h over 24 h (plus
avibactam) to achieve 100% TMIC over 4 weeks. Figure 3A shows the concentration-time
proﬁle achieved in duplicate HFS-TB, easily achieved in patients: as an example, the
same 24 MIU of penicillin administered by continuous infusion over 24 h achieved a
steady concentration of 80 mg/liter in serum. Figure 3B shows a surprising M. tuber-
culosis response curve with this regimen. First, there was a 2.88-log10 CFU/ml decline in
only the ﬁrst 2 days of therapy, or an EBA of 1.44 log10 CFU/ml/day. This EBA is 2.4 times
that of isoniazid, the ﬁrst-line drug with the highest EBA (24). Figure 3C demonstrates
similar ﬁndings based on TTP, which is inversely proportional to bacterial burden. There
was a 2.6-fold change in TTP on penicillin monotherapy in the HFS-TB. Second, Fig. 3B
and C demonstrate a lack of rebound growth on monotherapy, not seen until now with
TABLE 1 r2 for exposure index versus Mycobacterium tuberculosis burdena
Sampling day Peak/MIC AUC/MIC TMIC (%)
1 0.602 0.262 0.741
2 0.682 0.936 0.966
4 0.698 0.876 0.9
6 0.93 0.905 0.85
8 0.978 0.915 0.95
11 0.968 0.882 0.978
14 0.996 0.905 0.996
20 0.863 0.782 0.968
aThe highest r2 values were with TMIC throughout most of the experiment. The numbers in bold indicate the
PK/PD parameter with the highest r2 value for that sampling day.
Penicillin for Tuberculosis Antimicrobial Agents and Chemotherapy
February 2018 Volume 62 Issue 2 e02232-17 aac.asm.org 5
any ﬁrst-line drugs (24, 32, 34). This conﬁrms that at a TMIC of 100%, there was
suppression of both penicillin-resistant and penicillin-tolerant M. tuberculosis over 4
weeks of therapy.
Penicillin has a sterilizing effect against nonreplicating bacilli. The traditional
dogma is that penicillin microbial kill stops in stationary-phase bacteria and is best with
rapidly multiplying bacteria; thus, penicillin should not be effective against NRP or SDB
(35). Moreover, penicillin is labile at low pH, and some extracellular SDB in lung cavities
are at low pH (36–38). We compared the effect of penicillin (at a TMIC of 100%) plus
avibactam versus the standard three-drug regimen of isoniazid, rifampin, and pyrazi-
namide in the HFS-TB NRP model based on the streptomycin-dependent auxotroph M.
tuberculosis SS18b in acidiﬁed (pH 5.8) Middlebrook broth (23, 39). TheM. tuberculosis
strain penicillin MIC was 16 mg/liter, the rifampin MIC was 0.0625 mg/liter, the isoniazid
FIG 3 Bactericidal effect of continuous penicillin infusion. (A) As intended by this dosing strategy, the
concentrations were kept at 5 times MIC for 100% of the 24-h dosing interval, which means the optimal
dosing schedule for both microbial kill and resistance suppression. (B) Based on CFU counts, there was
a rapid decline in bacterial burden the ﬁrst 2 days, but instead of the usual rebound, the bacterial burden
stayed constant for 4 weeks. (C) The same pattern was apparent when TTP was used to measure bacterial
burden.
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MIC was 0.0156 mg/liter, and the pyrazinamide MIC was 12.5 mg/liter. M. tuberculosis
was inoculated into triplicate HFS-TB after 10 days of streptomycin deprivation; the
HFS-TB broth lacked streptomycin throughout the experiment. We measured the
antibiotic concentrations achieved in each HFS-TB, which revealed exposures shown in
Table 2. Figure 4A show the dramatic effect of penicillin-avibactam as a single agent,
which achieved kill below limits of detection (in CFU per milliliter) at the same rate as
combination standard therapy. Thus, penicillin killed7 log10 CFU/ml of nonreplicating
bacteria at acidic pH in the presence of avibactam, which was higher than the
concentration for log-phase-growth bacteria. However, when we used the more sen-
sitive TTP readout shown in Fig. 4B, the combination therapy reached negative cultures
faster than penicillin-avibactam.
Penicillin is additive and antagonistic to ceftazidime-avibactam. Avibactam is
currently coformulated with ceftazidime; thus, ceftazidime-avibactam is the most im-
TABLE 2 Exposures of anti-TB drugs achieved in HFS-TB replicates
Antibiotic MIC (mg/liter) TMIC (%) AUC/MIC ratio Peak/MIC ratio
Penicillin 16.0 100 587.6 27.52
Rifampin 0.06 100 915.40 86.66
Isoniazid 0.25 100 305.20 27.90
Pyrazinamide 12.5 100 110.00 7.09
FIG 4 Sterilizing effect of penicillin-avibactam versus standard therapy All error bars indicate SDs for
replicate HFS-TB units. (A) The decline in CFU/milliliter in the nontreated controls was because of the
volumes removed from the systems and number of times which we sampled the peripheral compart-
ment over 8 weeks of the experiment, which reduces the bacterial burden in a bacterial population that
is not replicating or growing. Based on the changes in CFU/milliliter changes, the effect of penicillin plus
avibactam was similar to that of the standard 3-drug regimen. (B) Based on TTP, the standard regimen
reached culture negativity on day 28, which was faster than penicillin-avibactam.
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mediate source of avibactam for clinical use. However, ceftazidime-avibactam itself has
very good anti-TB activity (17). We performed a HFS-TB with intracellular M. tuberculosis
H37Ra to determine if the combination kills more than each agent alone. Figure 5A
shows the bacterial burden as TTP over the 28 days of treatment. The nontreated
controls had progressively declining TTP with time, indicating growth, while the
combination of ceftazidime-avibactam plus penicillin had the highest TTPs, indicating
the lowest bacterial burden. Effect or kill was deﬁned as TTP on each sampling day
minus that on day 0 (pretreatment TTP). The TTP effect of ceftazidime-avibactam alone
on each day was added to that of penicillin-avibactam alone on that day to calculate
the expected additivity, which was compared to the TTP effect in HFS-TB replicates
treated with ceftazidime-avibactam plus penicillin (observed effect), based on Bliss
independence deﬁnitions (40). Figure 5B shows that expected additivity was similar to
observed effect in the ﬁrst 14 days, since 95% conﬁdence intervals overlapped. How-
ever, Fig. 5B shows that antagonism was encountered after day 21, since the observed
combination effect TTP difference was higher than the expected additivity TTP differ-
ence. Surprisingly, the pattern changed again on day 28, so that expected additivity
and observed effect were virtually similar. This means that additivity versus antagonism
versus synergy deﬁnitions depended on when the sampling was done and that these
change with duration of therapy. Nevertheless, Fig. 5B shows that the combination of
ceftazidime-avibactam plus penicillin resulted in higher kill than did either drug alone.
FIG 5 Additivity and antagonism of ceftazidime-avibactam with penicillin. (A) Error bars indicate SDs;
where error bars are not visible, they were smaller than the symbols used. Data are expressed as TTP,
which is a more sensitive assay than CFU. The nontreated controls grew well, as shown by decreasing TTP
as duration of therapy increased. The combination of penicillin-ceftazidime-avibactam had the highest
TTP on each sampling day, indicating the lowest bacterial burden. (B) Error bars are 95% conﬁdence
intervals. The bacterial burden on day of sampling minus that on day 0 gives the TTP change or effect.
The effect observed with the combination was compared to that for ceftazidime-avibactam and
penicillin-avibactam added together (expected additivity), which revealed overlapping 95% conﬁdence
intervals during the ﬁrst 2 weeks. On day 21, the observed effect was less than expected additivity, as
shown by nonoverlapping 95% conﬁdence intervals for the triplicate HFS-TB. This means antagonism.
However, the effect narrowed again on day 28.
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MDR-TB and incurable M. tuberculosis clinical strains are susceptible to peni-
cillin. It could be that the penicillin effect is conﬁned to M. tuberculosis laboratory
strains and that penicillin would have no effect on clinical multidrug-resistant M.
tuberculosis (MDR-TB) strains. Therefore, we sought to identify MICs for 25 clinical
strains, a mixture of 20% drug-susceptible strains and 80% MDR-TB/extremely drug-
resistant M. tuberculosis (XDR-TB) strains from South African patients. We examined this
using two assays, the reference broth microdilution test and the MGIT. The penicillin
MICs of the clinical strains are shown in Fig. 6A and B. The median MIC by either assay
FIG 6 Monte Carlo experiments and MIC distributions for dose ﬁnding. (A) Cumulative MICs using reference method for MIC identiﬁcation
in clinical isolates that are predominantly from M/XDR-TB. Ninety percent of isolates had MICs below 64 mg/liter. (B) Cumulative MIC
distribution based on MGIT assay. (C) Preterm children have relatively lower clearances and volumes of distribution, so higher
concentrations are achieved and for longer than in adults at comparatively lower doses. Doses of 10 to 15,000 U/kg/h are relatively
bunched up in performance, with a fall in PTA at an MIC of 64 mg/liter below 90% of patients. (D) In pregnant women in the third
trimester, the PTA falls below 90% at MIC of 32 mg/liter with 20,000 U/kg/h and at an MIC of 64 mg/liter at 30,000 U/kg/h. (E) In adult
patients not presently pregnant, the performance of different doses was similar to that in pregnant women. (F) The lowest doses above
which 90% of patients achieve or exceed the 65% TMIC target can be read from the graph and are 10,000U/kg/h for preterm children and
25,000 U/kg/h in adults. These are the doses that maximize bactericidal and sterilizing activity over the entire MIC distribution.
Penicillin for Tuberculosis Antimicrobial Agents and Chemotherapy
February 2018 Volume 62 Issue 2 e02232-17 aac.asm.org 9
was 2 mg/liter, and the MIC90 was 64 mg/liter. Since penicillin concentrations higher
than the MIC90 can be achieved in patients, these results mean that penicillin plus
avibactam could be effective against a large proportion of MDR-TB and XDR-TB strains.
The standard dose of penicillin would be effective in treating TB in the clinic.
Given this MIC distribution, how well would different doses of penicillin do in adult
patients with pulmonary TB, in pregnant women in the third trimester, or in preterm
neonates with disseminated TB in the clinic? Since TB clinical outcomes are mostly
driven by pharmacokinetic and MIC variability (41–49), we utilized the penicillin pop-
ulation pharmacokinetic parameter estimates and interindividual variability identiﬁed
by others (shown in Table 3) in 10,000-subject Monte Carlo experiments (MCE) in each
of ﬁve doses (50–52). Our aim was to identify the dose of penicillin that would achieve
the exposure of time above the MIC 65% in preterm babies with disseminated TB,
pregnant women with pulmonary TB, and nonpregnant adults with pulmonary TB,
treated using continuous infusion. Table 3 shows that the simulated population phar-
macokinetic parameters for 5 doses each (total of 50,000 simulated subjects for each
patient group) were similar to those in the initial domain of input, which is an internal
validation step.
Figure 6C shows the performance of each dosing regimen to achieve or exceed a
TMIC65% in infants of a gestational age of 32 weeks as the MIC increased. The
probability of target attainment (PTA) remained above 90% until an MIC of 64 mg/liter
in the highest dose in the children; even at an MIC of 128 mg/liter, the PTA for the
highest dose fell slightly below 90%. Figure 6D shows results for pulmonary TB in
pregnant women in the third trimester, which were similar to those in nonpregnant
adults (Fig. 6E). Figure 6F is a summation which shows the proportion of patients who
would achieve the TMIC target of 65% when all MICs were taken into account. Based
on Fig. 6F, the optimal dose in preterm children was 10,000 U/kg/h, while that in both
pregnant and nonpregnant adults was 25,000 U/kg/h. Therefore, these are the doses to
be administered in treatment of TB in these patient groups. In a sensitivity analysis, we
determined the optimal doses in adults if penicillin penetration into lung lesions was
only 50% (see Materials and Methods). The adult dose of 25,000 U/kg/h would still
achieve or exceed the target exposure in 80% of adults. The performance of avibac-
tam has been published before in our work on ceftazidime-avibactam (17).
DISCUSSION
Benzylpenicillin and penicillin V are arguably the safest antibiotics used in the
treatment of all infectious diseases. Billions of doses have been administered since the
1940s in diverse locales. The ﬁndings presented here suggest that penicillin-avibactam
alone or penicillin in combination with ceftazidime-avibactam has the potential to
improve both bactericidal and sterilizing effects and should be examined for the ability
to shorten treatment duration as part of multidrug TB regimens in patients. Treatment
shortening with reduction in relapse rates will impact transmission and disease burden
and allow more efﬁcient resource allocation; it is thus the research “holy grail” of TB
treatment. The advent and spread of XDR-TB and incurable TB, and emerging treatment
failures even with newer agents such as bedaquiline and delamanid, mean that newer
and repurposed agents are urgently required to provide therapeutic options for these
patients (53–55). MDR-TB and XDR-TB clinical isolates demonstrated good MICs; indeed,
the true MICs may even be lower given that penicillin degrades at a rate of about 10%
TABLE 3 Pharmacokinetic parameter estimates in domain of input versus 50,000-patient simulation output for each patient group
Group
Value for parameter in domain of input (% IIV) Output in >50,000-subject simulation (% IIV)
Total clearance (liters/h/kg) Central vol (liters/kg) Total clearance (liters/h/kg) Central vol (liters/kg)
Preterm infantsa 0.10 (16) 0.36 (39) 0.10 (124) 0.36 (105)
Pregnant women 0.25 (28) 0.27 (70) 0.25 (106) 0.27 (159)
Nonpregnant adults 0.3 (40) 0.52 (104) 0.31 (45) 0.52 (111)
aIn preterm infants, pharmacokinetic parameters were given for a two-compartment model, with domain of input versus mean value (interindividual variability [IIV]) of
0.774 liter/h/kg (40%) versus 0.733 liter/h/kg (102%) for intercompartmental clearance, and 0.152 liter/kg (17%) versus 0.151 liter/kg (105%) for peripheral volume.
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every 10 h in susceptibility test media, while M. tuberculosis has long doubling times
and the MIC assay takes several days to complete, conditions that caused falsely higher
MICs with another -lactam, ertapenem (56–58). Because benzylpenicillin was never
patented, and production costs have fallen over the decades, it costs very little and is
readily available across the world. It represents one of the least expensive repurposed
drugs for TB. On the other hand, continuous infusion imposes logistical and monetary
costs on patients and TB programs, which could counterbalance the low costs. More-
over, avibactam may further increase the cost of this combination.
There has been recent community advocacy calling for stakeholders to design
treatments for pregnant women with TB, given the dire need (59). TB in pregnant
women is associated with a 2-fold increase in premature birth and low birth weight and
a 6-fold-higher perinatal death rate (60). TB is responsible for 6% to 10% of all maternal
mortality in low-HIV-prevalence settings and 15 to 34% in high-HIV-prevalence settings
(60). There is currently no speciﬁc safe TB therapy targeted for this neglected and
vulnerable population. Though the ﬁrst-line drugs are considered to be fairly safe in
pregnancy, there have been reports of teratogenicity from rifampin (61, 62). Even
though current second-line drugs are known to adversely affect embryofetal develop-
ment, the CDC still recommends them for treatment of pregnant women, after coun-
seling the women, on the grounds that gains overwhelmingly outweigh the risks.
Benzylpenicillin-avibactam could help cure the TB in these women, with reduced fetal
toxicity risks. While penicillin crosses the placenta, it is not teratogenic, which has made
it the “go to” drug for pregnant women with different infections. While patient studies
are lacking for avibactam, the FDA label indicates that reproductive studies performed
during pregnancy in animal showed no adverse effects on embryofetal development
(63). Nevertheless, fetal toxicity from long-term administration of avibactam in people
has not been adequately studied. Thus, penicillin-avibactam could represent a break-
through for pregnant women suffering from TB.
Closely related is that congenital TB is an increasingly recognized problem, with the
children often born preterm (64). In the case of MDR-TB in children 6 years old, the
rates of ototoxicity with aminoglycosides are extremely high and devastating (65).
Indeed, even in adults with MDR-TB, the ototoxicity rates are up to 70% with amikacin
(66). Our ﬁnding that the use of the BlaC inhibitor avibactam allows penicillin to kill M.
tuberculosis opens the door to immediately test penicillin-avibactam efﬁcacy in chil-
dren. Penicillin is also already the go-to drug in infectious diseases of neonates, infants,
and toddlers. Our ﬁndings create opportunities to try combinations of other M.
tuberculosis BlaC inhibitors with penicillin.
Next, we wanted to make recommendations for how benzylpenicillin could be used
in neonates, pregnant women, and nonpregnant adults with TB, including in outpatient
settings. First, penicillin degrades to 90% in 13 h after reconstitution in normal saline
or sterile water for injection at room temperature, or when loaded onto a portable
pump reservoir and infused at 37°C for 1 day (67). However, when benzylpenicillin was
reconstituted with sodium citrate (a buffer) for the purpose of outpatient parenteral
antimicrobial therapy, concentrations remained above 90% when the drug was stored
at 3 to 5°C for 7 days and then kept at 37°C for 24 h (67, 75, 76). The outpatient strategy
would be to use this buffer and keep the solution refrigerated at 3 to 5°C for 7 days,
with the pump reservoir loaded daily. The recommend doses per day for a neonate,
pregnant woman, and nonpregnant adults are shown in Table 4. If normal saline or
water for injection is used as the diluent, the solution is refrigerated at 3 to 5°C for 7
days, and then the intravenous therapy would be loaded twice a day at doses shown
in Table 4, taking into account the degradation rates, which could impose a hardship
and likely necessitate inpatient care. Though the doses recommended are large, they
are not far from those used for other severe infections. In children with congenital
syphilis, for example, up to 300,000 U/kg/day (i.e., 12,500 U/kg/h) is used, and for adults
the penicillin dose we recommend is only 1.5 to 1.75 times that for those with infective
endocarditis.
Finally, the combination of ceftazidime-avibactam with penicillin resulted in higher
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kill rates than benzylpenicillin-avibactam alone. During early therapy the combination
was additive, but later on it became antagonistic. This remarkable ﬁnding has impli-
cations on general pharmacology studies examining drugs for synergy and antagonism.
Often, antibiotic pairs are presented as either antagonistic or synergistic. Here, we show
that the same concentrations may be additive or antagonistic depending on duration
of therapy! This is in addition to our prior ﬁndings in the HFS-TB and in patients that
anti-TB agents could be antagonistic or synergistic at the same time point in a
concentration-dependent fashion (42, 45, 46, 68). This means that deﬁnitions of syn-
ergy, additivity, and antagonism may need modiﬁcation. The question of double
-lactam coverage for TB that we have proposed is open to debate. For Gram-negative
bacilli, double -lactam coverage is sometimes used on the theory that binding of each
of the -lactams in the combination is on unique penicillin-binding proteins. It remains
to be seen whether this strategy will work for TB.
MATERIALS AND METHODS
Bacterial strains, cell lines, and growth conditions. The following laboratory M. tuberculosis strains
were used: H37Ra (ATCC 25177), H37Rv (ATCC 27294), and SS18b (donated by Stewart Cole), and 25
clinical strains from the South African Medical Research Council. Storage and culture conditions for
log-phase bacteria, SDB, and intracellular M. tuberculosis were as described in our prior studies (23, 68,
69). M. tuberculosis SS18b was ﬁrst cultured in Middlebrook 7H9 broth plus 10% OADC in the presence
of 50 mg/liter of streptomycin to achieve log-phase growth, followed by subculture in the same medium
but without streptomycin for 14 days. Human-derived THP-1 cells (ATCC TIB-202) grown in RPMI 1640
plus 10% fetal bovine serum FBS (RPMI-FBS) were infected with H37Ra for intracellular experiments in
wells and HFS-TB using methods as described previously but with a coincubation period of 3 h.
Materials and chemicals. Penicillin was purchased from Baylor University Medical Center pharmacy
(Dallas, TX). Avibactam was synthesized by BOC Sciences, Shirley, NY. Penicillin G-d7 was purchased from
Toronto Research Chemicals (Ontario, Canada). Hollow-ﬁber cartridges were obtained from FiberCell
(Frederick, MD).
Identiﬁcation of MICs. MICs were identiﬁed on two different occasions each, using the standard
broth macrodilution test and the MGIT. We used rifampin as a positive control for the drugs and M.
tuberculosis H37Rv as the control for bacterial isolates. The ﬁnal penicillin concentrations examined were
0, 0.5, 1, 2, 4, 8, 16, 32, 64, and 128 mg/liter, in combination with a ﬁnal ﬁxed avibactam concentration
of 15 mg/liter in triplicate, which is the peak concentration achieved with a 0.5-g clinical dose of
avibactam.
HFS-TB model. The construction of the HFS-TB has been described in detail previously (24, 31–34,
69–71). In all HFS-TB experiments, 20-ml M. tuberculosis cultures were inoculated into peripheral
compartments of HFS-TB. Penicillin and avibactam were administered via computerized syringe pumps,
based on dosing schedules described in legend of Figure 2. Sampling of the central compartment of each
system for drug concentrations was performed at 0, 1, 5, 7.5, 9, 11.5, 13, and 23.5 h after the ﬁrst dose
or start of the penicillin infusion, for the intracellular M. tuberculosis studies. In log-phase and NRP
experiments, the central compartment was sampled at 0, 10, and 23.5 h and 0, 1, 2, 3, 5, 11.5, 20, and
23.5 h after dose or start of infusion. Drug concentrations in the samples were measured as described
below. The peripheral compartment was sampled at 0 (before ﬁrst dose), 1, 2, 4, 6, 8, 11, 14, and 20 days
of therapy for THP-1 cell counts, number of viable cells, THP-1 cell volume, and culturing of the
intracellular M. tuberculosis, as described in the legend to Fig. 2. The peripheral compartment was
sampled for bacterial cultures on days 0, 2, 4, 6, 8, 10, 14, 21, and 26 for the log-phase study and days
0, 3, 7, 17, 24, 28, 40, 49, and 56 for NRP study, and bacterial burden was identiﬁed using both CFU counts
and TTP. Cultures of M. tuberculosis SS18b utilized Middlebrook 7H10 agar and broth supplemented with
50 mg/liter of streptomycin. Culture conditions were as described previously (24, 31–34, 69–71).
Penicillin concentration assay. Liquid chromatography-tandem mass spectrometry (LC-MS/MS)
analysis was performed using a Waters Acquity ultraperformance liquid chromatograph (UPLC) coupled
with Waters Xevo TQ mass spectrometer. Separation was achieved by injecting 2 l of sample on a
Waters Acquity UPLC HSS T3 column (50  2.1 mm; 1.8 m) using a binary gradient. Solvents for UPLC
were as follows: solvent A, 0.1% aqueous formic acid, and solvent B, 0.1% formic acid in acetonitrile.
Samples were diluted 1:20 with internal standard solution containing penicillin G-d7. The transitions used
TABLE 4 Recommended doses of benzylpenicillin for different patient populations
Patient group
Dose (U/kg/h) of benzylpenicillin
In sodium citrate buffer
(continuous infusion),
loaded once a day
In saline or sterile water, loaded
morning and evening
Neonates 10,000 10,000
Pregnant women 25,000 25,000
Nonpregnant adults 25,000 25,000
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were m/z 335  176 (penicillin G) and m/z 342  183 (penicillin G-d7). The between-day coefﬁcient of
variation (CV) for analysis of low and high (in parentheses) quality controls for RPMI-FBS were 2% (2%)
and 2% (2%) for saline, and those for Middlebrook 7H9 broth were 4% (2%). The within-day CV for
analysis of low and high (in parentheses) quality controls were 4% (2%) for RPMI-FBS, 2% (1%) for
Middlebrook 7H9 broth, and 2% (2%) for saline. The lower limits of quantitation were 0.25 mg/liter
for Middlebrook 7H9 broth for the nonreplicating persister and log-phase studies and 0.375 mg/liter in
RPMI-FBS and 0.05 mg/liter for saline (to measure intracellular concentrations). The avibactam, rifampin,
isoniazid, and pyrazinamide assays for concentration measurement have been described in detail
previously (17, 71).
Pharmacokinetic/pharmacodynamic modeling. Compartmental pharmacokinetic modeling was
employed for all HFS-TB studies, as described in detail previously (23, 24, 31, 33). Exposure response
relationships were examined using the inhibitory sigmoid Emax model for microbial kill and the quadratic
function for the relationship between drug-resistant subpopulation and exposure (23). All modeling was
performed using ADAPT 5 software (Biomedical Simulations Resource, University of Southern California).
Results were transferred to GraphPad Prism 7 for graphing purposes.
Monte Carlo experiments. Pharmacokinetic parameter estimates and interindividual variability as
percent CV in preterm infants with a gestational age of 32 weeks were from Muller et al., those for
pregnant women during the third trimester were from Johnson et al., and those for nonpregnant adults
were from Komatsu et al., shown in Table 1 (50–52). In the case of disseminated TB in preterm neonates,
the serum concentrations were used for the exposure calculations. Since the HFS-TB studies had been
performed using media with serum and albumin, we made no further adjustments for protein binding.
In the case of adult pulmonary TB, there are no recent proper pharmacokinetic studies on the epithelial
lining ﬂuid or infected lung tissue concentration of penicillin. In 1950, Jensen et al. (77) noted that the
benzyl ester of penicillin achieved high concentrations in the lungs, unlike earlier penicillin. Similarly,
studies by Ungar and Muggleton using mice and guinea pigs with bacterial pneumonia revealed that
unlike normal lung, the concentration-time proﬁles achieved in infected lung tissue by benzylpenicillin
exceeded those in serum 2-fold (72). Around the same time, Heathcote and Nassau noted that in
patients treated with benzypenicillin who had lung resection, the lung tissue concentrations at the time
of pulmonary artery ligation were 1- to 2-fold higher than in serum from simultaneous blood draw (73).
We took a conservative approach and assumed a 1:1 ratio in effective concentration in lungs of TB
patients versus serum, based on up to 2-fold drug penetration and 50% protein binding of penicillin. For
sensitivity analysis, we assumed we were 50% overoptimistic in our assumptions based on ELF pene-
tration calculated using compartmental pharmacokinetic approach for the ureidopenicillin, piperacillin
(74). For each drug these population pharmacokinetic parameter estimates, and the covariance, were
used as the domain of input in subroutine PRIOR of ADAPT. Simulations were run for each dose for
10,000 patients, for each group of patients, so that50,000 patient pharmacokinetics were simulated for
preterm children alone, pregnant women alone, and adults not presently pregnant (i.e., 160,000 in all).
We generated 24-h concentration-time proﬁles for patients on continuous infusion with each dose, and
then at each MIC we calculated the PTA for a TMIC of65%. In order to calculate the proportion of 10,000
patients who achieved this target when treated by each dose, we took an expectation over the entire MIC
distribution, as detailed previously (17).
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